Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Rating of “Hold” by Brokerages

Corcept Therapeutics Incorporated (NASDAQ:CORT) has been assigned an average rating of “Hold” from the eight brokerages that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $77.1667.

A number of equities research analysts recently issued reports on the company. HC Wainwright reduced their price target on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a report on Wednesday, December 31st. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, January 23rd. Truist Financial set a $50.00 target price on Corcept Therapeutics in a report on Wednesday, December 31st. Finally, UBS Group assumed coverage on Corcept Therapeutics in a research report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target on the stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: COR T’s Korlym revenue momentum: Zacks highlights a 13% Y/Y sales rise for Korlym in 2025 and projects 2026 revenue of $900M–$1B, suggesting solid underlying product sales even as competitive and legal risks persist. Korlym revenue article
• Neutral Sentiment: Short‑interest data published for early March appears inconsistent/zero (likely a data/reporting glitch) and does not provide clear evidence of increased shorting pressure at this time — investors should treat those figures cautiously. (Multiple short‑interest entries in news feed showed 0 shares / NaN changes.)
• Negative Sentiment: Hagens Berman and other firms: A securities class action (Allegheny County Employees’ Retirement System v. Corcept et al.) was flagged this week alleging the company and executives misled investors, citing FDA warnings and “evidence gaps” around the Relacorilant NDA that previously triggered a ~50% stock drop. Lead‑plaintiff deadline is April 21, 2026. Hagens Berman notice
• Negative Sentiment: Multiple plaintiff firms (Bronstein, Rosen, Pomerantz, Schall, Glancy, DJS, ClaimsFiler, etc.) have issued alerts encouraging investors to join/lead the class action based on purchases between Oct 31, 2024 and Dec 30, 2025 — this amplifies media attention and could increase settlement/defense costs and management distraction. Example: Bronstein notice. Bronstein notice
• Negative Sentiment: Schall/Rosen/Pomerantz & others reiterate class‑period and April 21 deadline; aggregated press releases increase likelihood of large plaintiff turnout and publicity — a material near‑term catalyst pressuring the stock. Example: Schall Law Firm reminder. Schall Law Firm notice

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 8,233 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $35.99, for a total value of $296,305.67. Following the transaction, the insider directly owned 2,231 shares of the company’s stock, valued at $80,293.69. This trade represents a 78.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 48,233 shares of company stock worth $1,817,306 in the last 90 days. Corporate insiders own 20.80% of the company’s stock.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Advisory Services Network LLC bought a new position in Corcept Therapeutics in the third quarter valued at approximately $25,000. Clearstead Advisors LLC lifted its stake in Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 193 shares during the last quarter. Golden State Wealth Management LLC bought a new stake in Corcept Therapeutics during the second quarter worth $28,000. Hantz Financial Services Inc. boosted its holdings in shares of Corcept Therapeutics by 598.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 395 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in shares of Corcept Therapeutics by 2,326.3% in the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 442 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics Price Performance

Shares of Corcept Therapeutics stock opened at $33.87 on Monday. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $3.60 billion, a price-to-earnings ratio of 41.31 and a beta of 0.29. Corcept Therapeutics has a twelve month low of $28.66 and a twelve month high of $117.33. The company has a 50-day simple moving average of $39.59 and a two-hundred day simple moving average of $64.47.

Corcept Therapeutics (NASDAQ:CORT) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a return on equity of 15.19% and a net margin of 12.96%.The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $254.94 million. During the same quarter in the previous year, the company earned $0.26 EPS. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. Analysts forecast that Corcept Therapeutics will post 1.36 EPS for the current year.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.